Drug Trial Radar · NCT07623824
A Phase III Clinical Trial to Evaluate the Efficacy and Safety of Octreotide Long-acting Injection in Patients With Acromegaly
Last checked: Nov 20, 2026Latest source record: Jun 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
154
Planned (sponsor's estimate)
Start
May 31, 2026
Primary completion
Jul 31, 2029
Study completion Dec 30, 2029
Sponsor
- Lead sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jun 3, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
he purpose of this study is to evaluate the efficacy and safety of SYHX2008 injection in in patients with acromegaly.
Conditions
- Diagnosed With Acromegaly, Currently in the Active Stage of the Disease
Interventions
SYHX2008Drug
The patients will accept SYHX2008 injection by subcutaneous administration.A treatment period of 28 weeks.
Sandostatin LAR®Drug
The patients will accept Sandostatin LAR@ by intra-muscular administration.A treatment period of 28 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- The proportion of patients with an IGF-1 index ≤ 1.0Time frame: Week 28
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.